American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

dc.contributor.author

Brandow, Amanda M

dc.contributor.author

Carroll, C Patrick

dc.contributor.author

Creary, Susan

dc.contributor.author

Edwards-Elliott, Ronisha

dc.contributor.author

Glassberg, Jeffrey

dc.contributor.author

Hurley, Robert W

dc.contributor.author

Kutlar, Abdullah

dc.contributor.author

Seisa, Mohamed

dc.contributor.author

Stinson, Jennifer

dc.contributor.author

Strouse, John J

dc.contributor.author

Yusuf, Fouza

dc.contributor.author

Zempsky, William

dc.contributor.author

Lang, Eddy

dc.date.accessioned

2020-07-01T20:04:34Z

dc.date.available

2020-07-01T20:04:34Z

dc.date.issued

2020-06

dc.date.updated

2020-07-01T20:04:34Z

dc.description.abstract

BACKGROUND:The management of acute and chronic pain for individuals living with sickle cell disease (SCD) is a clinical challenge. This reflects the paucity of clinical SCD pain research and limited understanding of the complex biological differences between acute and chronic pain. These issues collectively create barriers to effective, targeted interventions. Optimal pain management requires interdisciplinary care. OBJECTIVE:These evidence-based guidelines developed by the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in pain management decisions for children and adults with SCD. METHODS:ASH formed a multidisciplinary panel, including 2 patient representatives, that was thoroughly vetted to minimize bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including updating or performing systematic reviews. Clinical questions and outcomes were prioritized according to importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS:The panel reached consensus on 18 recommendations specific to acute and chronic pain. The recommendations reflect a broad pain management approach, encompassing pharmacological and nonpharmacological interventions and analgesic delivery. CONCLUSIONS:Because of low-certainty evidence and closely balanced benefits and harms, most recommendations are conditional. Patient preferences should drive clinical decisions. Policymaking, including that by payers, will require substantial debate and input from stakeholders. Randomized controlled trials and comparative-effectiveness studies are needed for chronic opioid therapy, nonopioid therapies, and nonpharmacological interventions.

dc.identifier

460974

dc.identifier.issn

2473-9529

dc.identifier.issn

2473-9537

dc.identifier.uri

https://hdl.handle.net/10161/21137

dc.language

eng

dc.publisher

American Society of Hematology

dc.relation.ispartof

Blood advances

dc.relation.isversionof

10.1182/bloodadvances.2020001851

dc.title

American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

dc.type

Journal article

duke.contributor.orcid

Strouse, John J|0000-0003-0341-1457

pubs.begin-page

2656

pubs.end-page

2701

pubs.issue

12

pubs.organisational-group

School of Medicine

pubs.organisational-group

Pediatrics, Hematology-Oncology

pubs.organisational-group

Medicine, Hematology

pubs.organisational-group

Duke

pubs.organisational-group

Pediatrics

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Medicine

pubs.publication-status

Published

pubs.volume

4

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Brandow ASH SCD Pain Guidelines Blood Adv 20.pdf
Size:
1.6 MB
Format:
Adobe Portable Document Format
Description:
Published version